Emory University/Children's Healthcare of Atlanta
Emory University/Children's Healthcare of Atlanta
Atlanta, Georgia, United States3 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, brain disorder, brainstem cancer, central nervous system cancer, central nervous system disorder, diffuse intrinsic pontine glioma, epithelial neoplasm, glioma, neoplasm, nervous system disorder, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 2 | 2026-09-21 | NCT06838676 | |
| COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction | Cardiovascular Abnormalities, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Pulmonary Atresia, Ventricular Outflow Obstruction, aortic valve disorder, aortopulmonary window, cardiovascular disorder, congenital heart disease, heart disorder, heart septal defect, heart valve disorder, persistent truncus arteriosus, pulmonary valve insufficiency, pulmonary valve stenosis, tetralogy of fallot, transposition of the great arteries, vascular malformation | Recruiting | Not applicable | 2026-07-23 | NCT02744677 | |
| Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, DNA Virus Infections, Epstein-Barr virus infection, Herpesviridae infectious disease, Infections, Primary Immunodeficiency Diseases, Tumor Virus Infections, adenoviridae infectious disease, cytomegalovirus infection, hereditary disease, immune system disorder, inborn error of immunity, viral infectious disease | Active, not recruiting | Phase 1 / Phase 2 | 2025-05-11 | NCT03475212 |